Trial · NCT07898696
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
NCT07898696, Not applicable, Recruiting, Prof Muzaffar Ali Zahidi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial. Trials, record NCT07898696. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898696
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
- NCT number
- NCT07898696
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 660 participants, estimated
- Lead sponsor
- Prof Muzaffar Ali Zahidi
- Conditions
- ST-Elevation Myocardial Infarction (STEMI)
- Interventions
- Adenosine, Standard Treatment only
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Slow-Flow or No-Reflow After PPCI | During the primary PCI procedure, immediately after completion of PCI (Day 1) | The proportion of participants with slow-flow or no-reflow on final post-PCI angiography, assessed using the Thrombolysis in Myocardial Infarction (TIMI) flow grade. Slow-flow/no-reflow is defined as final TIMI flow grade 0, 1, or 2 in the treated infarct-related artery, in the absence of a mechanical cause of impaired coronary flow. |
| Secondary | Final TIMI Flow Grade | During the primary PCI procedure, immediately after completion of PCI (Day 1) | Thrombolysis in Myocardial Infarction (TIMI) Flow Grade ranges from 0 to 3. Grade 0 indicates no antegrade coronary flow, while Grade 3 indicates normal coronary flow. Higher scores indicate better coronary blood flow. |
| Secondary | Myocardial Blush Grade After Primary PCI | During the primary PCI procedure, immediately after completion of PCI (Day 1) | Myocardial Blush Grade ranges from 0 to 3. Grade 0 indicates no myocardial blush, while Grade 3 indicates normal myocardial perfusion. Higher scores indicate better myocardial perfusion. |
| Secondary | Incidence of Major Adverse Cardiovascular Events (MACE) | At the time of Hospital Discharge (upto 10 Days) and at 30 days after PCI. | Proportion of participants experiencing a major adverse cardiovascular event, defined according to the study protocol as death, periprocedural myocardial infarction, or target-vessel revascularization (TVR). Events will be assessed during the index hospitalization and through 30 days after PCI. |
| Secondary | Safety of Prophylactic High-Dose Intracoronary Adenosine | During the primary PCI procedure, immediately after completion of PCI (Day 1) & at time of Hospital Discharge (upto 10 Days) and at 30 days after PCI. | Incidence of adverse events associated with the study intervention, including clinically significant bradycardia, atrioventricular block, hypotension, and other adverse events specified in the study protocol. |
| Secondary | Left Ventricular Ejection Fraction at Discharge and 30 Days | At the time of Hospital Discharge (upto 10 Days) and at 30 days after PCI. | Left ventricular ejection fraction (LVEF), expressed as a percentage, assessed using echocardiography at hospital discharge and at 30-day follow-up. |
| Secondary | Six-Minute Walk Distance at 30 Days | 30 days after PCI. | Functional exercise capacity assessed by the six-minute walk test. The distance walked in meters during six minutes will be recorded at the 30-day follow-up visit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898696
GET https://conductscience.org/api/trials/v1/NCT07898696/registered